Amprius Adds CAMINUS as U.S. Contract Manufacturer for Silicon-Anode Pouch Cells

What happened

Amprius Technologies has signed a contract manufacturing agreement with CAMINUS (formerly EnPower) to produce its silicon-anode pouch cells at CAMINUS's Indianapolis facility, expanding domestic production capacity for aviation, defense, and uncrewed systems customers. This agreement follows the company's earlier partnership with Nanotech Energy and aligns with its capital-light outsourced manufacturing strategy, which seeks to reduce capex intensity while scaling output. The master report had noted that Amprius is dependent on partner qualification and yield, and that NDAA compliance and supplier friction are key risks. Adding a second U.S.-based partner incrementally addresses domestic sourcing concerns but does not eliminate execution risk, as CAMINUS must still qualify Amprius's cell designs and achieve production yields. With $36.5 million in remaining performance obligations and a $140 million 2026 revenue target, the new capacity could support order conversion, but the market will look for evidence of successful line qualification and on-time delivery.

Implication

The addition of CAMINUS provides another potential route to NDAA-compliant production, which could strengthen Amprius's defense-related revenue prospects and reduce reliance on overseas partners. However, contract manufacturing agreements are only as good as the partner's ability to achieve qualified output and yield, and no production or revenue from CAMINUS has been demonstrated yet. Investors should monitor upcoming disclosures for any indication of qualification progress, initial purchase orders, or delays, as well as the company's Q3 2026 results to assess whether the outsourced model can support the at least $140 million revenue and 28% gross margin guidance. Until concrete evidence emerges that new manufacturing partners are converting demand into cash without margin erosion or working-capital strain, the stock remains fairly valued near $11.20 relative to the $9 attractive entry and $16 trim level. The agreement is a positive but incremental development that reinforces the need for proof of execution rather than altering the risk-reward balance.

Thesis delta

The core thesis remains unchanged: Amprius's growth is real but hinges on converting outsourced production into durable margin and cash. This agreement does not shift that thesis; it adds one more unproven partner to the manufacturing network. The bar for a rating change remains execution evidence in Q3 2026 and beyond, not partnership announcements.